U.S. stock night trading volatility: Jasper Therapeutics fell 3% in after-hours trading, with executives disclosing their holdings intensively attracting attention

U.S. Stock Night Market Movements

Jasper Therapeutics fell 3.00% in the night market. Based on recent news,

1. On July 21, Jasper Therapeutics director Patrick J. Crutcher reported an initial Form 3 filing for 518,331 shares of common voting stock. This news may trigger market attention on changes in the company's internal holdings, leading to stock price fluctuations.

2. On July 23, Jasper Therapeutics Chief Operating Officer Matthew E. Ros reported options for 103,204 shares of common voting stock, with an exercise price of $0.01 per share. This news may draw market attention to the company's executives' holdings and option exercises, further impacting the stock price.

3. On July 24, Jasper Therapeutics Chief Medical Officer Greg Keenan disclosed options for 103,204 shares of common voting stock, with an exercise price of $0.01 per share. This news may attract market attention to the company's executives' holdings and option exercises, further affecting the stock price. The market is closely watching the company's upcoming quarterly financial report.

Stocks with High Trading Volume in the Industry

Gilead Sciences fell 0.71% in the night market. Based on recent news,

1. On July 21, Leerink Partners downgraded Gilead Sciences' rating from "Outperform" to "Market Perform," and lowered the target price from $146 to $127, citing resistance to growth in the HIV preventive medication market. This news led to a decline in stock price.

2. On July 22, Gilead Sciences announced that its BDR program in Brazil would undergo a mandatory stock split, changing the ratio of BDRs to underlying stocks from 1:2 to 1:12. This news raised market concerns about the company's future financial performance, resulting in a drop in stock price.

3. On July 22, Gilead Sciences projected that its second-quarter financial report would incur $11.2 billion in expenses due to the acquisition of internal R&D assets, which would have a one-time negative impact on earnings per share, further pressuring the stock price. Competition in the HIV treatment market is intensifying, and macroeconomic uncertainties are increasing.

Regeneron Pharmaceuticals fell 1.03% in the night market. Based on recent news,

1. On July 22, Hagens Berman law firm announced an investigation into Regeneron Pharmaceuticals, potentially involving internal violations. This news raised market concerns, leading to a decline in stock price.

2. On July 21, MarketBeat reported that although Regeneron Pharmaceuticals is currently rated "Moderate Buy" by analysts, top analysts believe there are five other stocks that are more worthy of investors' attention. This news weakened market confidence in Regeneron Pharmaceuticals, further pressuring the stock price On July 21, Telix Pharmaceuticals announced its financial report, indicating that its strategic partnership with Regeneron Pharmaceuticals and global business expansion support the revenue expectations for the fiscal year 2026. However, despite the promising outlook for the partnership, the market remains cautious about Regeneron Pharmaceuticals' short-term performance. The market holds a cautious attitude towards Regeneron Pharmaceuticals' short-term performance.

Q32 Bio fell 3.06% in after-hours trading, with a transaction volume reaching $9,586, and there have been no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation